Neuroscience innovations
We are creating a healthier future for the billions of people worldwide living with nervous system disorders and seek to redefine what’s possible in neuropsychiatric, neurodegenerative, ophthalmic and autoantibody diseases.
That’s why we’re building on our nearly 70 years of work in neuroscience to pioneer the next era of precise, differentiated and impactful treatments – so people have the freedom to live a life filled with joy, independence and dignity. Hope starts here.
That’s why we’re building on our nearly 70 years of work in neuroscience to pioneer the next era of precise, differentiated and impactful treatments – so people have the freedom to live a life filled with joy, independence and dignity. Hope starts here.
Innovating in Health&Care
-
More than memory loss: 5 things we now know about Alzheimer’s disease
Scientists are better understanding the neuropsychiatric changes that strike up to 97% of patients diagnosed with this degenerative brain disease. Here’s what to know about these often distressing symptoms, and why Johnson & Johnson is working on a solution. -
Moving toward a more personalized approach to treating depression
The World Health Organization predicts that depression will be the leading cause of disability across the globe by 2030. Learn how Johnson & Johnson is on a mission to change that.
-
“Reimagining what life with schizophrenia could look like”
Johnson & Johnson’s Leonardo Diaz, M.D., addresses common misconceptions about schizophrenia, the critical importance of preventing relapse and why there’s so much optimism about treatments. -
Why can bipolar disorder go undiagnosed for years?
The condition affects 36 million people around the world, yet it can be surprisingly difficult to recognize—for both patients and healthcare professionals. Learn why Johnson & Johnson continues to advance approaches for this often-misunderstood mental health disorder.
-
When depression improves but patients still grapple with symptoms
Only one in three people with major depressive disorder achieves remission after their first antidepressant, leaving many to continue to experience life-impacting symptoms such as disrupted sleep, changes in weight and appetite and trouble concentrating. Learn why Johnson & Johnson is working to help more patients achieve remission. -
Is this the end of one-size-fits-all treatments for depression?
Learn how Johnson & Johnson is working to better address the needs of the 7 in 10 people with depression whose treatments aren’t providing enough relief. -
Inside the Ireland facility revolutionizing the way stroke care is approached
Strokes claim millions of lives each year. But innovative research is making treatments more effective and helping neurovascular patients lead longer, fuller lives.